MindWalk Holdings (HYFT) Other Working Capital Changes (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Other Working Capital Changes of $44675.3 for Q1 2026, down 90.11% year-over-year from $451537.6 in Q1 2025, and down 49.62% quarter-over-quarter from $88668.1 in Q4 2025.
MindWalk Holdings (HYFT) Other Working Capital Changes (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Other Working Capital Changes for 4 consecutive years, with $44675.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 90.11% year-over-year to $44675.3; the TTM figure through Jan 2026 stood at $806855.6 (down 20.9% YoY), while the FY2021 annual figure was -$214089.0, changed N/A from the prior year.
- Other Working Capital Changes fell to $44675.3 in Q1 2026 per HYFT's latest filing, from $88668.1 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $428291.5 in Q1 2025 and bottomed at -$630185.3 in Q1 2023.
- Historically, Other Working Capital Changes has averaged $1877.8 across 4 years, with a median of $39303.8 in 2024.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes tumbled 137.1% — and 2025, when it jumped 615.16%.
- MindWalk Holdings' Other Working Capital Changes stood at $350309.6 in 2023, then decreased by 14.08% to $300970.7 in 2024, then slumped by 70.54% to $88668.1 in 2025, then sank by 49.62% to $44675.3 in 2026.
- Business Quant data shows HYFT's Other Working Capital Changes at $44675.3 in Q1 2026, $88668.1 in Q4 2025, and $221974.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 322,441.66 |
| Apr 30, 2026 | 322,441.66 |
| Apr 30, 2026 | 322,441.66 |
| Jan 31, 2026 | -501,516.51 |
| Jan 31, 2026 | -501,516.51 |
| Jan 31, 2026 | -501,516.51 |
| Oct 31, 2025 | 134,083.49 |
| Oct 31, 2025 | 134,083.49 |
| Oct 31, 2025 | 134,083.49 |
| Jul 31, 2025 | -239,441.37 |
| Jul 31, 2025 | -239,441.37 |
| Jul 31, 2025 | -239,441.37 |
| Apr 30, 2025 | -89,246.54 |
| Apr 30, 2025 | -89,246.54 |
| Apr 30, 2025 | -89,246.54 |
| Jan 31, 2025 | 428,291.53 |
| Jan 31, 2025 | 428,291.53 |
| Jan 31, 2025 | 428,291.53 |
| Oct 31, 2024 | 53,457.08 |
| Oct 31, 2024 | 53,457.08 |